NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

AEK, thank you for posting this article from today’s Financial Times. This article seems to support the belief that because DCVax-L was approved for the Specials Program in the UK, the MHRA could already be reviewing the DCVax-L approval application on a rolling basis, and it could be approved within 150 days (5 months) of final submission:

The UK is trying to attract more life sciences investment post-Brexit, with the newly independent regulator establishing an initiative to cut the time it takes to get treatments approved. For drugmakers granted the special status, the regulator will review data on a rolling basis and deliver a decision within 150 days of the final submission.